These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 16772349)

  • 61. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
    Liu D; Liu Z; Condouris S; Xing M
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2264-71. PubMed ID: 17374713
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
    Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.
    Chuang TC; Chuang AY; Poeta L; Koch WM; Califano JA; Tufano RP
    Head Neck; 2010 Feb; 32(2):229-34. PubMed ID: 19626635
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
    Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
    Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
    [TBL] [Abstract][Full Text] [Related]  

  • 65. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea.
    Ahn HY; Chung YJ; Kim BS; Kang KH; Seok JW; Kim HS; Park SJ; Cho BY
    Surgery; 2014 Apr; 155(4):689-95. PubMed ID: 24612623
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
    Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 70. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAF
    Poyrazoğlu Ş; Bundak R; Baş F; Yeğen G; Şanlı Y; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):185-193. PubMed ID: 28077340
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The prevalence and prognostic value of BRAF mutation in thyroid cancer.
    Kebebew E; Weng J; Bauer J; Ranvier G; Clark OH; Duh QY; Shibru D; Bastian B; Griffin A
    Ann Surg; 2007 Sep; 246(3):466-70; discussion 470-1. PubMed ID: 17717450
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.
    Cradic KW; Milosevic D; Rosenberg AM; Erickson LA; McIver B; Grebe SK
    J Clin Endocrinol Metab; 2009 Dec; 94(12):5001-9. PubMed ID: 19850689
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.
    Trovisco V; Soares P; Preto A; de Castro IV; Lima J; Castro P; Máximo V; Botelho T; Moreira S; Meireles AM; Magalhães J; Abrosimov A; Cameselle-Teijeiro J; Sobrinho-Simões M
    Virchows Arch; 2005 Jun; 446(6):589-95. PubMed ID: 15902486
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma.
    Salvatore G; Giannini R; Faviana P; Caleo A; Migliaccio I; Fagin JA; Nikiforov YE; Troncone G; Palombini L; Basolo F; Santoro M
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5175-80. PubMed ID: 15472223
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
    Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
    Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.
    Brzeziańska E; Pastuszak-Lewandoska D; Wojciechowska K; Migdalska-Sek M; Cyniak-Magierska A; Nawrot E; Lewiński A
    Neuro Endocrinol Lett; 2007 Aug; 28(4):351-9. PubMed ID: 17693984
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.
    Angell TE; Lechner MG; Jang JK; Correa AJ; LoPresti JS; Epstein AL
    Thyroid; 2014 Sep; 24(9):1385-93. PubMed ID: 24955518
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression.
    Grabellus F; Worm K; Schmid KW; Sheu SY
    Thyroid; 2012 Apr; 22(4):377-82. PubMed ID: 22376167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.